Biopharma financings rebounded strongly in Q1 2026, reaching $22.82 billion, up roughly 74% year over year, according to reported totals. The data show financing activity recovering from a softer 2025, while remaining below earlier peak levels from 2021 and 2024. Separately, the broader market backdrop indicates improving IPO momentum early in 2026, setting a more constructive environment for late-stage biotechs to access public capital.